Using Becaplermin Gel with Collagen Products to Potentiate Healing in Chronic Leg Wounds
- 0 Comments
- 6854 reads
Disclosures: This study was unsupported and unsolicited. Dr. Carson is an occasional speaker for Healthpoint, Ltd., Fort Worth, Texas. This work was presented at The Wound Healing Society’s 13th Annual Educational Symposium and Exhibition, May 5, 2003, Seattle, Washington.
Becaplermin gel (Regranex®, Johnson & Johnson Wound Management, Somerville, New Jersey) a genetically engineered, platelet-derived growth factor (PDGF) that mimics human PDGF, has been approved for use in diabetic lower-extremity ulcers since 1997. Becaplermin also appears to be effective in nondiabetic patients with chronic wounds, and it is frequently used in these patients.[2–4] Becaplermin gel’s effect on chronic wounds is often less than stunning, often taking months to show a progression to healing in many series. The cost for a 15-ounce tube varies from $350.00 to $500.00 in the authors’ area (Southern California).
Early in the use of becaplermin gel on chronic wounds of the legs, the authors were thwarted by the original instructions to change the dressing every 12 hours. In this outpatient setting, many patients were unable or unwilling to cooperate with this plan. As a result, the authors noted that many wounds would dry out or become contaminated before the next visit. Consequently, the authors began to try alternate methods for application of becaplermin. The original concept in the authors’ use of collagen with becaplermin was to provide a longer-lasting, moist dressing that would protect the becaplermin gel and the wound. Extraneous collagen often derived from bovine or swine sources has been used for decades as an adjunct for wound healing. Exact mechanisms of collagen’s assistance in wound healing remain to be precisely defined, but its useful effects are well known. The authors felt that collagen might also potentiate the duration of effect of becaplermin by providing a slower release of becaplermin and by slowing the destruction of the becaplermin.
All formulations of collagen did not appear equally effective when used in this manner, and the authors chose to use two collagen products with becaplermin gel based on preliminary trial and error. These preparations were Fibracol Plus® (collagen-alginate, Johnson & Johnson Wound Management, Somerville, New Jersey) and Oasis® (small intestinal submucosa [SIS], Healthpoint, Ltd., Fort Worth, Texas). The collagen-alginate product is a combination of 10-percent alginate and 90-percent collagen, and SIS is derived from submucosa of porcine small intestine.[6,7] As this treatment appeared efficacious in diabetic patients, the authors expanded the treatment to include nondiabetic patients as well. This was done with the provision that the patients had not responded to collagen or becaplermin gel alone and had other known factors that interfered with wound healing (e.g., ischemia, poor nutrition, pressure, and infection) corrected as much as possible.
All of the patients had wound care involving maintenance debridement and moist dressings and failed to show signs of healing. In some instances, ultrasound, electrical stimulation, hyperbaric oxygen, and vacuum-assisted closure had also been used without a significant healing response. Criteria of a significant healing response were decrease in wound size, proliferation of granulation tissue, absence of heavy or foul discharge, and absence of progressive or recurring necrosis.
Materials and Methods
Thirty-six consecutive patients over a three-year period with wounds that failed to heal by other wound care techniques were treated simultaneously with becaplermin gel and a collagen product (18 collagen-alginate and 18 SIS). Initially, patients were treated with collagen-alginate, but as its availability diminished, SIS was used as it became more readily available. All patients gave informed consent for their specific procedures and their treatments.
References 1. Smiell JM, Wieman J, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower-extremity, diabetic ulcers: A combined analysis of four randomized studies. Wound Repair Regen 1999;7:335–46. 2. Harrison-Balestra C, Eaglstein WH, Falabela AF, Kirsner RS. Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: A retrospective series. Dermatol Surg 2002;28(8):755–9; discussion 759–60. 3. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: A phase II, randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999;7(3):141–7. 4. Mandracchia VJ, Sanders SM, Frerichs JA. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers: A retrospective analysis. Clin Podiatr Med Surg 2001;18(1):189–209, viii. 5. Mian M, Beghe F, Mian E. Collagen as a pharmacological approach in wound healing. Int J Tissue React 1992;14 (Suppl):1–9. 6. Donaghue VM, Chrzan JS, Rosenblum BI, et al. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care 1998;11(3):114–9. 7. Brown-Etris M, Cutshall WD, Hiles MC. A New biomaterial derived from small intestine submucosa and developed into a wound matrix device. Wounds 2002;14(4):150–66. 8. Krasner DL. How to prepare the wound bed. Ostomy Wound Manage 2001;47(4):59–61. 9. Falanga V. Wound bed preparation and the role of enzymes: A case for multiple actions of therapeutic agents. Ostomy Wound Manage 2001;47(4):59–61. 10. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995;21:71–81. 11. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974;71(4):1207–10. 12. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46(2):155–69. 13. Heldin CH, Westermark B. Platelet-derived growth factors: A family of isoforms that bind to two distinct receptors. Br Med Bull 1989;45(2):453–64. 14. Pollock RA, Richardson WD. The alternative-splice isoforms of the PDGF A-chain differ in their ability to associate with the extracellular matrix and to bind heparin in vitro. Growth Factors 1992;7:267. 15. Kelly JL, Sanchez A, Brown GS, et al. Accumulation of PDGF B and cell-binding forms of PDGF A in the extracellular matrix. J Cell Biol 1993;121(5):1153–63. 16. Claesson-Welsh L. Signal transduction by the PDGF receptors. Prog Growth Factor Res 1994;5(1):37. 17. Cohen MA, Eaglstein WH. Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermatol 2001;45(6):857–62. 18. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: A phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen 1999;7(3):141–7. 19. Pierce GF, Tarpley JE, Tseng J, et al. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995;96(3):1336–50. 20. Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19(7):767–78. 21. Perry BH, Sampson AR, Schwab BH, et al. A meta-analytic approach to an integrated summary of efficacy: A case study of becaplermin gel. Control Clin Trials 2002;23(4):389–408. 22. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implications. J Am Acad Dermatol 1994;31(1):49–53. 23. Pachence JM. Collagen-based devices for soft tissue repair. J Biomed Mater Res 1996;33(1):35–40. 24. Palmieri B. Heterologous collagen in wound healing: A clinical study. Int J Tissue React 1992;14 (Suppl):21–5. 25. Kolenik SA, McGovern TW, Leffell DJ. Use of a lyophilized bovine collagen matrix in postoperative wound healing. Dermatol Surg 1999;25(4):303–7. 26. Horch RE, Stark GB. Comparison of the effect of a collagen dressing and a polyurethane dressing on the healing of split thickness skin graft (STSG) donor sites. Scand J Plast Reconstr Surg Hand Surg 1998;32(4):407–13. 27. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002;137(7):822–7. 28. Cullen B, Smith R, McCulloch E, et al. Mechanism of action of Promogran, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002;10(1):16–25. 29. Wlaschek M, Peus D, Achterberg V, et al. Protease inhibitors protect growth factor activity in chronic wounds. Br J Dermatol 1997;137(4):646. 30. Ovington L, Cullen B. Matrix metalloprotease modulation and growth factor protection. Wounds 2002;14(5 Suppl):3S–13S. 31. Gallea-Robache S, Morand V, Millet S, et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997;9(5):340–6. 32. Fivenson D, Robson K, Choucair M. Multimodal therapy for approaching difficult-to-heal wounds. Wounds 2001;13(6):223–8.